©2022 Stanford Medicine
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
Trial ID: NCT00313079
A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety, pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with vincristine.
A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Adult Patients With Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
3.1.1 Age Patients must be >= 18 years old at the time of study entry.
184.108.40.206 Histologic Verification Patients must have had histologic verification of B-lineage
ALL with bone marrow relapse or refractory disease that is unresponsive to traditional
220.127.116.11 For patients WITHOUT prior allogeneic BMT:
1. Second or subsequent bone marrow relapse
2. Primary refractory marrow disease
3. M3 marrow (>25% blasts) or >25% leukemic blasts in peripheral blood
18.104.22.168 For patients WITH prior allogeneic BMT:
1. First or subsequent bone marrow relapse post-BMT
2. M3 marrow or M2 (>5 % and <25% blasts) if cytogenetic or VNTR confirmation
3.1.3 Confirmation of antibody reactivity 22.214.171.124 Patient's leukemic blasts (peripheral
blood or marrow) must be documented to bind mAb 216 in vitro (Teng lab) 126.96.36.199 Patient's
RBC documented to NOT express fetal "i" antigen and RBC shown to NOT bind mAb 216 in vitro
3.1.4 Patient Must Not Be Eligible For Therapies of Higher Priority
3.1.5 Performance Level (See Appendix I) Karnofsky >= 50%
3.1.6 Life Expectancy Must be at least 8 weeks.
3.1.7 Prior Therapy Patients must have fully recovered from the acute toxic effects of all
prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
1. Myelosuppressive chemotherapy: Must not have received within one week of entry onto
2. Biologic, including monoclonal antibodies: At least 2 weeks since the completion of
therapy with a biologic agent including monoclonal antibodies.
3. Hydroxyurea can be used up to 72 hours before study entry
3.1.8 Organ Function Requirements
188.8.131.52 Bone Marrow Function: 184.108.40.206.1 No hematologic criteria for WBC, Hgb or platelets
220.127.116.11.2 Patients with thrombocytopenia should be responsive to platelet transfusions and
must not have uncontrolled bleeding.
18.104.22.168 Adequate Renal Function Defined As:
- A serum creatinine that is less than or equal to 2 x normal for age
22.214.171.124 Adequate Liver Function Defined As:
- Total bilirubin <= 2 x upper limit of normal (ULN) for age, and
- SGPT (ALT) <= 5 x upper limit of normal (ULN) for age
126.96.36.199 Adequate Cardiac Function Defined As:
- Shortening fraction of >= 27% by echocardiogram, or
- Ejection fraction of >= 50% by gated radionuclide study.
188.8.131.52 All patients must sign a written informed consent. 184.108.40.206 All institutional (IRB)
and FDA requirements for human studies must be met.
3.2.1 CNS 3 or refractory CNS leukemia
3.2.2 Isolated extramedullary relapse
3.2.3 Uncontrolled infection
3.2.4 Lack of mAb 216 binding to patient's leukemic blasts in vitro
3.2.5 Binding of mAb 216 to the "i" antigen on patient's erythrocytes
drug: MAb 216
School of Medicine
300 Pasteur Drive
Stanford, CA 94305